Daniel is currently the Chief Executive Officer of DBV Technologies, a clinical-stage biopharmaceutical company specializing in immunotherapy products. Daniel is a non-executive director of REGENXBIO Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.
Daniel was Chairman and Chief Executive Officer of Ikaria, Inc. until its acquisition by Mallinckrodt Pharmaceuticals in April 2015. He had served as Ikaria’s President and CEO since 2008, and was appointed Chairman of the Board of Directors in October 2009. Daniel oversaw the spinout of Bellerophon Therapeutics from Ikaria in 2013, creating two companies to best leverage the scientific, financial, and marketing strengths of the company. Daniel also served as Chairman and CEO of Alcresta Therapeutics, a privately held company developing and commercializing novel enzyme based therapies for patients with gastro-intestinal and rare diseases, until November 2018.
Until the sale of Ikaria, Daniel was a member of the Board of Directors and Health Section Governing Board of the Biotechnology Industry Organization (BIO), where he participated on the bioethics, regulatory environment, and reimbursement committees, and a Board Director of PhRMA, where he participates on the FDA and Biomedical Research Committee.
Prior to joining Ikaria, Daniel served as General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International. Earlier in his career, he held a number of senior management positions at GlaxoSmithKline (GSK); from 2001 to 2004, he was Vice President and Regional Director for Australasia at GSK.
Daniel holds a B.S. in Biochemistry from the University of Montreal.
Member of the Audit Committee
Member of the Remuneration Committee